Navigation Links
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
Date:3/6/2013

NEW YORK, March 6, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Impax Laboratories Inc. ("Impax" or the "Company") (NasdaqGS: IPXL). The investigation focuses on whether the Company and its executives violated federal securities laws.

On March 4, 2013, Shares of Impax dropped $4.10, or 20.5 percent, to $15.90 in aftermarket trading following the Company's announcement that the FDA issued a new Form 483 with twelve observations, three of which are designated as repeat observations from past inspections. New and pending applications that relate to the Hayward, California manufacturing facility may be withheld by the FDA until the Form 483 problems are solved. The FDA sent Impax a warning letter in January 2011 based on an inspection of the Hayward, Calif., plant, and found other problems in a March 2012 inspection. The March 2012 inspection, the FDA said the original problems had been addressed, but it found problems in its quality control laboratory. Shares of Impax stock were down over 25% in early trading on March 5, 2013 from its prior days close. 

If you are aware of any facts relating to this investigation, or purchased shares of Impax, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman , 212-697-6484
eitan@bgandg.com


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
5. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones ... estate planning process, or where to even begin. “Now more than ever there are ... to properly protect yourself and your family,” said attorney Lisa Edgar Dickman, founder of ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... ... April 21, 2017 , ... Each year, everyone is ... day to clean, plant trees and look forward to a better future. However, supporting ... doing something outdoors. Indoor air quality can be two to five times more polluted ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana Fiber ... bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering Multi-Gigabit data ... consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet access now ...
Breaking Medicine News(10 mins):